Company Update (NASDAQ:CPRX): Catalyst Pharmaceuticals Inc Announces Launch of Expanded Access Program Website and Participation at the American Association of Neuromuscular & Electrodiagnostic Medicine Conference
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) announced the launch of a new website for its expanded access program (EAP) and its planned participation at the 63rd American Association of Neuromuscular & Electrodiagnostic Medicine(AANEM) conference which will be held on September 14-17, 2016 at the Hilton New Orleans Riverside in New Orleans.
This week Catalyst officially launched its new Expanded Access Program website at www.muscleweakness-eap.com. Catalyst’s EAP continues to enroll new patients and provide Firdapse® (amifampridine phosphate) at no charge to eligible patients with Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS). Expanded Access Programs are not required by regulatory agencies, but are a mechanism supported by them for getting investigational treatment to patients who have a life threatening or severely debilitating disease and who cannot be satisfactorily treated with an alternative therapy approved by the FDA. This new website is designed to make it even easier and transparent for patients to learn about Catalyst’s Expanded Access Program and the possibility of getting access to Firdapse at no cost if they are eligible.
“As part of our ongoing commitment to patients, Catalyst is fully dedicated to our Expanded Access Program and focused on making Firdapse more accessible to the patients who need it,” said Patrick J. McEnany, Chief Executive Officer of Catalyst Pharmaceuticals. “We hope this new website enables more patients with LEMS and CMS to understand our program and learn more about this experimental treatment option for these debilitating diseases.”
Catalyst will have a booth in the exhibition hall (Booth #212) of the AANEM conference. (Original Source)
Shares of Catalyst Pharmaceutical are down nearly 5% to $0.923 in pre-market trading. CPRX has a 1-year high of $4.52 and a 1-year low of $0.51. The stock’s 50-day moving average is $0.89 and its 200-day moving average is $0.88.
On the ratings front, H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on CPRX, in a report issued on June 14. According to TipRanks.com, Fein has a yearly average return of 15.5%, a 51% success rate, and is ranked #156 out of 4163 analysts.
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette’s disorder.